De-risk RNA programs from design to testing
Eclipsebio provides the RNA biology expertise and proprietary analytical technologies that drug developers and researchers need to make confident decisions. From AI-powered sequence design to nucleotide-level characterization, 300+ partners across pharma, biotech, and academia trust us to deliver insights they can act on.
RNA solutions across modalities:
Whether you're developing small oligonucleotides, targeting RNA with small molecules, training AI models, or advancing fundamental RNA research, we have the analytical depth to support your program.
AI Training Data
To support accurate AI model training for drug discovery, we provide high-quality, reproducible datasets through our eVERSE platform.
Small Oligonucleotides
With our holistic approach to small oligonucleotide design and validation, we provide RNAi and ASO developers with the data needed for clinical success. Learn how we perform multiomic profiling of targets and robustly measure off-target effects.
Small Molecules
Our integrative portfolio of assays reveals disease-specific, accessible regions of target RNAs and provides deep profiling of on-target and off-target therapeutic effects.
Basic Research
For our academic partners, we provide a la carte and integrative solutions that deliver a comprehensive view of RNA biology, from secondary structure to protein regulation.
Proprietary assays.
Nucleotide-level resolution.
Our sequencing-based analytics reveal what standard QC methods miss: the exact nucleotide positions where impurities originate, where structure changes during formulation, and where translation stalls. Each assay generates data you can act on.
End-Seq
Map unique regulatory regions
eRibo Pro
Measure transcription and translation
eSENSE dsRNA
Measure and reduce dsRNA contamination
eSENSE m6A
Map regions of RNA methylation
eSHAPE
Directly determine RNA structure
m6A-eCLIP
Locate specific methylated bases
miR-eCLIP+
Identify miRNA binding and siRNA off-targets
Nanopore
Long-read RNA sequencing
RBP-eCLIP
Identify where and how proteins bind
What Our Partners Say
"Eclipsebio’s analysis of RNA folding has provided valuable insights necessary to understand the impact of RNA sequence and chemical modifications on secondary structures… to help improve the design of our RNAs and rationalize our internal findings."
"Eclipsebio was the only company that could perform the robust siRNA off-target binding analysis we needed. Their experimental results provided important additional insights into our own internal findings. We look forward to continuing to work with Eclipsebio in the future."
"Eclipsebio has been an invaluable partner to Deep Genomics. They've helped us generate massive miRNA-related datasets for training AI models, and have designed and conducted bespoke assays to illuminate the mechanism underlying some of our lead therapeutic compounds."
"At Acuitas we are interested in how modifications to LNP formulations can impact efficacy and stability. Eclipsebio’s eSHAPE assay has potentially revealed direct correlations between LNP composition and RNA secondary structure, further adding to our understanding of the mechanism of action for RNA-LNP systems."
New at Eclipsebio
Introducing eCOMPASS
Our integrated platform for RNA drug development brings AI-powered design, rapid prototyping, and sequencing-first analytics into one iterative workflow. See how the design-make-characterize loop works.
AI-ready RNA datasets
eVERSE delivers next-generation sequencing data tailored for AI model training in drug discovery. High-quality, reproducible datasets built on 9 years of RNA biology expertise.
Learn with our newest blog
Discover how our eCOMPASS platform helps develop optimal RNA therapeutics by pairing AI-powered design with sequencing-based analytics.
Upcoming events
Our team of RNA experts is presenting at conferences and webinars on RNA solutions and partnership opportunities.